Company / Profit Margin
Neurocrine Biosciences Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
16.7%
FY2025
5-year range
7.9% / 38.9%
FY2021-FY2025
Trend
+15.5%
vs FY2024
Sector context
#31 of 145
Health Care
What the data says
Neurocrine Biosciences's profit margin of 16.7% is higher than 79% of companies in the Health Care sector (FY2025). Profit Margin has fluctuated over the past 9 years, ranging from -940.6% in FY2016 to 38.9% in FY2022.
Based on SEC 10-K filings.
16.7% in FY2025 with a 5-year CAGR of -22.2%. Top quartile in the Health Care sector.
Improved from 13.2% to 16.7% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -22.2pp
- 5-Year Change
- -22.2pp
- 10-Year Change
- -
Sector benchmark
Top 21% in Health CareTop 21% of 145This company 16.7% Sector average -792.7%
▼
+102.1% above sector average
Key checks
Key Insights
- In FY2025, profit margin increased 15.5% year-over-year.
- Currently 809.4pp above the Health Care sector average.
- Peak profit margin was recorded in FY2022.
- Lowest profit margin in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 16.7% | +15.5% |
| FY2024 | 14.5% | +9.5% |
| FY2023 | 13.2% | -66.0% |
| FY2022 | 38.9% | +392.9% |
| FY2021 | 7.9% | -79.7% |
| FY2020 | 38.9% | +730.3% |
| FY2019 | 4.7% | +0.2% |
| FY2018 | 4.7% | - |
| FY2017 | - | - |
| FY2016 | -940.6% | -109.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026